Otilimab Biosimilar – Anti-CSF2, GM-CSF mAb – Research Grade

Description of Otilimab Biosimilar - Anti-CSF2, GM-CSF mAb - Research Grade

Introduction

Otilimab Biosimilar, also known as Anti-CSF2, GM-CSF mAb, is a research grade monoclonal antibody that has shown promising results in the treatment of various inflammatory and autoimmune diseases. In this article, we will delve into the structure, activity, and potential applications of this novel therapeutic agent.

Structure of Otilimab Biosimilar

Otilimab Biosimilar is a recombinant, humanized monoclonal antibody that specifically targets the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF). It is composed of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 150 kDa. The antibody is produced using Chinese hamster ovary (CHO) cells and is glycosylated, meaning it has sugar molecules attached to it. This glycosylation is important for the stability and activity of the antibody.

Activity of Otilimab Biosimilar

As mentioned earlier, Otilimab Biosimilar targets GM-CSF, a cytokine that plays a crucial role in the development and activation of immune cells. By binding to GM-CSF, Otilimab Biosimilar blocks its activity, leading to a reduction in the production and activation of inflammatory cells such as neutrophils, macrophages, and dendritic cells. This results in a decrease in the levels of pro-inflammatory cytokines and chemokines, ultimately leading to a decrease in inflammation.

Applications of Otilimab Biosimilar

Otilimab Biosimilar has shown promising results in various pre-clinical and clinical studies as a potential treatment for inflammatory and autoimmune diseases. Some of the conditions it has been studied for include rheumatoid arthritis, psoriasis, multiple sclerosis, and asthma.

Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and destruction of joints. Otilimab Biosimilar has been shown to significantly reduce disease activity in patients with moderate to severe RA, as well as improve physical function and reduce joint damage. It has also been well-tolerated in clinical trials, with a favorable safety profile.

Psoriasis

Psoriasis is a chronic skin disease caused by an overactive immune system. In a phase II clinical trial, Otilimab Biosimilar was found to be effective in reducing the severity of psoriasis, with a significant improvement in skin lesions and symptoms. It was also well-tolerated, with no serious adverse events reported.

Multiple Sclerosis

Multiple sclerosis (MS) is an autoimmune disease that affects the central nervous system. Otilimab Biosimilar has shown promising results in reducing the number of relapses and slowing disease progression in patients with relapsing-remitting MS. It has also been shown to improve brain lesions and physical functioning in these patients.

Asthma

Asthma is a chronic respiratory disease characterized by airway inflammation and narrowing. Otilimab Biosimilar has been studied as a potential treatment for severe asthma, with promising results. It has been shown to reduce asthma exacerbations and improve lung function in patients with uncontrolled asthma.

Conclusion

In conclusion, Otilimab Biosimilar, also known as Anti-CSF2, GM-CSF mAb, is a research grade monoclonal antibody with a unique structure and mechanism of action. It has shown promising results in various inflammatory and autoimmune diseases, making it a potential therapeutic option for these conditions. Further research and clinical trials are needed to fully understand the efficacy and safety of this novel antibody, but it holds great potential in improving the lives of patients with these debilitating diseases.

Otilimab Biosimilar - Anti-CSF2, GM-CSF mAb binds to Human CSF2/GM-CSF in indirect ELISA Assay

Immobilized CSF2 / GM-CSF (in Mammalian), C-His, recombinant protein (cat. No. PX-P5667) at 0.5µg/mL (100µL/well) can bind Otilimab Biosimilar - Anti-CSF2, GM-CSF mAb (cat. No. PX-TA1141) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 152.1M.